Mibavademab for adult women whose periods stopped due to brain hormone signals

Who can take part

• Diagnosis of FHA after exclusion of anatomic or organic causes of amenorrhea
• Has had no menstrual bleeding episode within 3 months prior to day 1, as described in the protocol
• Has a Body Mass Index (BMI) ≥18.5 and <25 kg/m\^2 at screening, or BMI ≥25 to <30 kg/m\^2 at screening AND percentage of body fat <23% from rigorous exercise as determined by the investigator through Standard of Care (SoC) methods (eg, skinfold thickness, DXA, bioimpedance) within 6 months of screening

Who cannot take part

• Has uterine (eg, absence of uterus, prior endometrial ablation, endometriosis, outflow tract disorders) or ovarian conditions (eg, absence of an ovary, presence of large polycystic ovaries i.e. greater than 10 cc) that impact assessment of menses or of the HPO axis
• Has presence of primary amenorrhea (failure to reach menarche, first menstrual cycle)
• Has conditions other than FHA that may cause amenorrhea or menstrual cycle disturbances (eg, polycystic ovarian syndrome, hyperprolactinemia, primary ovarian insufficiency, untreated primary hypothyroidism, primary hyperthyroidism), as described in the protocol
• Has blood estradiol ≥50 pg/mL or blood progesterone ≥1 ng/mL at screening, as described in the protocol
• Polycystic ovarian morphology with an ovarian volume >10 cc on TransVaginal UltraSound (TVUS) [or TransAbdominal Pelvic Ultrasound (TAPU) if applicable] at baseline
• Presence of follicle ≥17 mm, evidence of ruptured follicle, and/or evidence of corpus luteum on TVUS (or TAPU if applicable) at baseline; NOTE: Other protocol-defined Inclusion/Exclusion criteria apply